Track Moleculin Biotech's long-term debt ($150K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), MBRX shows a long-term debt of $150K. That compares with $290K in the prior-year period — down 49.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MBRX's long-term debt is now $150K (was $290K) — a 49.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Moleculin Biotech is outperforming or lagging.
Tracking MBRX's long-term debt over time shows whether Moleculin Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $150K That compares with $290K in the prior-year period — down 49.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Moleculin Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $150K) with ownership activity and broader fundamentals.
Moleculin Biotech's long-term debt is $150K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.